Author name: Walid

BALTIMORE, June 4, 2020 /PRNewswire/ — Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines, received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for its lead candidate, EXG4217, was approved on May 23, 2020. […]

BALTIMORE, July 9, 2018 – Elixirgen Therapeutics, Inc. raised $4 million in a Series A funding round from University of Tokyo Edge Capital (UTEC). Elixirgen Therapeutics, Inc. is a biotechnology company founded by Minoru Ko, M.D., Ph.D., that is focused on curing humanity’s ailments through innovations in stem cell biology. Elixirgen Therapeutics is pursuing cures

BALTIMORE, May 7, 2018 – Elixirgen Therapeutics, LLC has now incorporated to become Elixirgen Therapeutics, Inc. This change makes the company a better target for investment from strategic partners or venture capital, which will in turn help the company to further its goals in developing and commercializing its therapies.

BALTIMORE, May 30, 2017 – Elixirgen Therapeutics has successfully concluded its pre-IND meeting with the U.S. Food and Drug Administration (FDA) for inherited bone marrow failure syndromes (IBMFS), including Dyskeratosis Congenita (DC) and Fanconi Anemia (FA). IBMFS such as DC and FA are rare genetic disorders known for their aplastic anemia, which hinders blood cell